Yunsoo Kim

Array ( [id] => 14960779 [patent_doc_number] => 20190307867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => ANTI-ABETA THERAPEUTIC VACCINES [patent_app_type] => utility [patent_app_number] => 16/379322 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19396173 [patent_doc_number] => 12070502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-27 [patent_title] => Process for reducing subvisible particles in a pharmaceutical formulation [patent_app_type] => utility [patent_app_number] => 16/377371 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12301 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16377371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16760444 [patent_doc_number] => 20210106025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => Method for separation of proteins naturally occurring in mammalian milk [patent_app_type] => utility [patent_app_number] => 16/982088 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570628 [patent_doc_number] => 20210009634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => FULL FLOW-THROUGH PROCESS FOR PURIFYING RECOMBINANT PROTEINS [patent_app_type] => utility [patent_app_number] => 17/040702 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578567 [patent_doc_number] => 20190216892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => HISTONE DEACETYLASE (HDAC) INHIBITOR UP-REGULATES CAR EXPRESSION AND TARGETED ANTIGEN INTENSITY, INCREASING ANTITUMOR EFFICACY [patent_app_type] => utility [patent_app_number] => 16/360785 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531829 [patent_doc_number] => 20190201535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/298474 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14498095 [patent_doc_number] => 20190192702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/298202 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413169 [patent_doc_number] => 11667702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Stable aqueous formulations of aflibercept [patent_app_type] => utility [patent_app_number] => 16/297387 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 81069 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14775101 [patent_doc_number] => 20190262448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => Cationic Oil-In-Water Emulsions [patent_app_type] => utility [patent_app_number] => 16/295563 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16295563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657415 [patent_doc_number] => 20210054051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => METHODS FOR PURIFYING RECOMBINANT POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/977142 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746835 [patent_doc_number] => 20190256591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => STABILIZED ANTIBODY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/294506 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16294506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715639 [patent_doc_number] => 20190248883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) [patent_app_type] => utility [patent_app_number] => 16/280393 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16280393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682461 [patent_doc_number] => 20190240345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => NOVEL STABLE FORMULATION [patent_app_type] => utility [patent_app_number] => 16/274015 [patent_app_country] => US [patent_app_date] => 2019-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16274015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17799070 [patent_doc_number] => 11413337 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Peptide conjugated particles for the treatment of inflammation [patent_app_type] => utility [patent_app_number] => 16/272775 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 89 [patent_no_of_words] => 26514 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175463 [patent_doc_number] => 20190358323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/270381 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17177375 [patent_doc_number] => 11154604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Adjuvant compositions and related methods [patent_app_type] => utility [patent_app_number] => 16/267273 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14107 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17586571 [patent_doc_number] => 11324813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Indoleamine 2,3-dioxygenase based immunotherapy [patent_app_type] => utility [patent_app_number] => 16/261114 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 35 [patent_no_of_words] => 27563 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175461 [patent_doc_number] => 20190358322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => PROTEIN FORMULATIONS AND METHODS OF MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/228478 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501353 [patent_doc_number] => 20190194331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => ANTI-VLA1 (CD49A) ANTIBODY PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/227564 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19564772 [patent_doc_number] => 12139533 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Liquid formulations of anti-CD200 antibodies [patent_app_type] => utility [patent_app_number] => 16/954868 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 4 [patent_no_of_words] => 26865 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954868 [rel_patent_id] =>[rel_patent_doc_number] =>)